Personal Injury Attorneys - Manhattan, Brooklyn, Queens, Long Island and the Bronx

The recall applies to 359 different lots (as many as 359 million strips) of glucose test strips marketed under the following brand names: Precision Xceed Pro, Precision Xtra, Medisense Optium, Optium, OptiumEZ, and ReliOn Ultima. These strips are used with Abbotts blood glucose monitoring systems. The test strips being recalled may give falsely low blood glucose results. False results may lead patients to try to raise their blood glucose unnecessarily, or they may fail to treat elevated blood glucose because of a false, low reading. Both scenarios pose risks to a patients health.

The U.S. Food and Drug Administration recommends that special attention be paid to signs and symptoms of high blood sugar (hyperglycemia) and low blood sugar (hypoglycemia).

Working in consultation with the United States Food and Drug Administration (FDA), McNeil Consumer Healthcare is implementing a voluntary recall of infant and childrens liquid products due to manufacturing deficiencies which may affect quality, purity or potency. Some of the manufacturing deficiencies include products that may contain a higher concentration of active ingredient than specified; others that contain inactive ingredients that may not meet internal testing requirements; and others that may contain tiny particles. Parents and caregivers are advised by the U.S. Food and Drug Administration to stop using these products. Instead, there a number of other products on the market, including generic versions of the recalled products, which are intended for use in infants and children and are not affected by the recall. The FDA states that the potential for serious medical problems is remote. However, if your child exhibits any unexpected symptoms after use of

Last week, just one week before the opening of Michael Moores new movie, Capitalism: A Love Story, the U.S. Food and Drug Administration (FDA) admitted what has been known for a while that its approval of the Menaflex device in December, 2008, came after intense political pressure from politicians made just months after they received significant campaign contributions from the manufacturer of Menaflex. In issuing its approval, the FDA overrode the agencys scientific reviewers who repeatedly and unanimously over many years decided that the device was unsafe because the device often failed, forcing patients to get another operation. This was the first time that the agency publicly questioned the process behind one of its approvals, admitted that a regulatory decision was influenced by politics, and accused a former commissioner of questionable cond

In a press release dated June 16, 2009, the U.S. Food and Drug Administration (FDA) advised consumers to stop use of three over-the-counter Zicam Cold Remedy products: nasal gel, nasal swabs and the discontinued "kids size" swabs. The FDA’s advisory stated that the products are associated with the loss of sense of smell, called anosmia. Anosmia may be long-lasting or permanent. In addition to a loss of the sense of smell, patients have also complained of a loss of the sense of taste. The FDA has received more than 130 reports of loss of sense of smell associated with the use of these three Zicam products.   Many people experienced a loss of smell said the condition with the first dose; others reported a loss of the sense of smell after multiple uses. The active ingredient in Zicam is Zincum Gluconicum (Zinc Gluconate) which can cause nasal nerve damage.   If you notice a burning sensation in the nasal cavity or a loss of smell or taste while using Zicam, stop usingÂ